U.S. Residential REITs Stock News

Sirius XM Holdings (SIRI) has been on the radar lately after its stock price dipped nearly 3% in a single day, sparking fresh debate among shareholders about what is driving the latest moves. While there is not one headline-grabbing event behind this shift, the recent drop is hard to ignore for anyone following the satellite radio space. Whether you are holding shares or thinking about getting in, this price action is a good reminder to revisit what is happening under the hood at Sirius...

In August 2025, Akero Therapeutics announced the publication of final 96-week results from its Phase 2b HARMONY trial in The Lancet, showing that efruxifermin improved both fibrosis and metabolic health in adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis. The data suggest efruxifermin may address multiple risk factors in MASH, including cardiovascular risks, highlighting its potential as a comprehensive therapy currently undergoing Phase 3...

Thinking about what to do with Coca-Cola stock? You are not alone. With its status as one of the most recognizable consumer brands in the world, Coca-Cola often finds itself at the crossroads of value and potential. Lately, the stock price has offered some signals that are worth a closer look. Over the last month, shares have inched up nearly 0.9%, and year to date, KO is up about 14.3%. While the last quarter saw a minor dip, this was against a fairly stable broader market mood and growing...

Rhythm Pharmaceuticals (RYTM) just received a significant decision from the FDA, as their supplemental New Drug Application for setmelanotide was not only accepted for filing but also granted Priority Review status. This indicates that the agency sees potential for the medication to address an urgent, unmet need for people dealing with acquired hypothalamic obesity. Investors familiar with Rhythm know setmelanotide already has approvals for rare genetic obesity disorders. This proposed...

DENTSPLY SIRONA Inc. announced its second quarter 2025 results in August, revealing sales of US$936 million and a net loss of US$45 million, with management reaffirming its full-year sales guidance of US$3.60 billion to US$3.70 billion amid continued industry headwinds. An interesting aspect is the board’s decision to maintain its dividend at US$0.16 per share, contrasting with ongoing revenue pressure and signaling a commitment to shareholder returns despite financial challenges. We’ll...

Thinking about investing in Vulcan Materials, or maybe deciding whether to hold on to your shares? You are in good company. Vulcan Materials has caught the attention of market watchers, especially after its stock price shrugged off some short-term dips and delivered an impressive 16.4% return over the past year. That is a performance hard to ignore, especially when you look at its nearly 143% total return over five years. Recent months have shown a blend of resilience and optimism, with the...

If you have your eye on Live Nation Entertainment stock, you are not alone. With concerts and live experiences roaring back, investors have seen the company’s share price climb an impressive 25% so far this year and over 67% over the past twelve months. That kind of run naturally raises the question: does LYV have more room to run, or is the market already pricing in all that potential? Digging a bit deeper, LYV’s journey has been anything but boring. In just the past three months, the stock...

NasdaqGS:JD 1 Year Share Price vs Fair Value Explore JD.com's Fair Values from the Community and select yours JD.com...

Thinking about what to do with Pony AI stock? You are not alone. As one of the more intriguing names in the autonomous vehicle sector, Pony AI has experienced its fair share of twists and turns recently. For traders and long-term investors alike, the past few months have brought some big price swings that demand a closer look. Let us start with the numbers. After a dip of nearly 28% over the past 90 days, Pony AI has rebounded with a 15.6% climb over the last month. That recent rally, coupled...

Thinking about whether to hold, buy, or sell Oracle? You are in good company. Oracle’s stock has experienced considerable volatility, with short-term dips but significant growth over the past year. In just the last 90 days, shares are up almost 50%, and that one-year return is nearly 70%. Clearly, something notable is happening behind the scenes. What is driving these swings? For one, Oracle continues to secure major deals and draw investment headlines. Over the past month, news broke that...

Thinking about what to do next with Johnson Controls International stock? You are not alone. Investors have been watching JCI’s distinct price action over the past year and weighing up the company’s future, especially as expectations across the industrial sector keep shifting. After a rollercoaster 2023, the past twelve months have brought a substantial total return of about 53% for Johnson Controls’ shareholders. That impressive run comes in addition to a hefty 104% return over three years,...

General Mills (GIS) just slipped into headlines after another dip, as shares gave up roughly half a percent at the close. The move might seem modest, but it is enough to catch some investors’ attention, especially for those watching the food sector’s defensive names. Without a single event behind the slide, it does raise the question: are traders simply recalibrating expectations, or is something bigger brewing under the surface? If you pan out, the bigger story comes into focus. Over the...

Key Insights TROOPS' significant insider ownership suggests inherent interests in company's expansion A total of 3...

O’Reilly Automotive recently completed a buyback tranche, repurchasing 9,404,000 shares for US$857.19 million between April and August 2025, finalizing a very large buyback program that started in 2011. This substantial completion of the repurchase initiative signals management’s ongoing confidence in the company’s long-term performance and their commitment to returning capital to shareholders. With the buyback program now complete, we’ll consider how returning capital to shareholders could...

If you are trying to make sense of Insulet’s recent run, you are not alone. Whether you already hold shares or are weighing a new buy, it is tough to look away from a stock that has powered up nearly 30% year-to-date and delivered a whopping 79% total return over the past year. The buzz makes sense, with Insulet’s sales up by more than 14% and annual net income growth topping 23%. All of this comes with the shares closing recently at $333, just a modest 5.7% below the average analyst price...

If you held shares of Uranium Energy (UEC) over the past month, you probably noticed your portfolio got a boost. The stock climbed nearly 17% in that period. There has been no game-changing headline or sudden corporate announcement to spark this run, but that kind of momentum is enough to get any investor wondering if the market sees value others have missed, or if this is just another blip in a volatile sector. This move fits into a bigger picture of rising momentum for Uranium Energy,...

On August 12, 2025, Insmed Incorporated announced that the U.S. FDA approved BRINSUPRI (brensocatib), the first and only FDA-approved oral therapy for non-cystic fibrosis bronchiectasis in adults and children 12 years and older, with Maxor Specialty Pharmacy later selected as a limited distribution provider. This approval not only introduces a first-in-class treatment for an underserved patient population but also positions Insmed to potentially establish a new standard of care for...

If you have been following Cigna Group (CI) lately, you’ve probably noticed the stock’s share price drifting higher. The increase has been subtle, but just enough to catch the eye. There hasn’t been a single major announcement sparking this move; however, with a share price now sitting above $300 and a year-to-date gain over 10%, many investors are wondering whether the recent momentum is revealing something about sentiment or simply reflects the normal ebb and flow of a maturing company...

Something caught your eye with Northern Trust (NTRS) today? While there is no breaking development triggering an abrupt move, this recent bump in the share price might have some investors wondering if market optimism is building or simply reacting to shifting expectations. In moments like this, it pays to look under the hood and see if this near-term momentum matches up with the underlying business or if we are just seeing market noise. Over the past year, Northern Trust stock has recorded a...

W. R. Berkley (WRB) just unveiled Berkley Edge, a brand-new operation dedicated to serving small and mid-sized businesses with professional liability and casualty insurance, especially in cases that are tough to underwrite. This move, along with the appointment of industry veteran Jamie Secor to lead the venture, is a clear statement about where the company sees opportunity: in specialty insurance, targeting risks that many competitors pass by. For investors, this expansion is worth a closer...

If you are sitting on the fence about what to do with BWX Technologies stock right now, you are definitely not alone. With its impressive run over the last year, climbing more than 63%, BWXT has landed squarely on the radar for many investors searching for growth stories and stable plays alike. The stock’s gains are even more eye-catching when you zoom out, doubling over the last three and five years, and surging more than 51% in just the past three months. These outsized returns tell a story...

It is not every day that Novo Nordisk (NYSE:NVO) catches eyes for all the wrong reasons, but this week’s slide has certainly prompted investors to pause. The stock dropped by roughly 0.9% in the past day and now sits a staggering 58% below its level a year ago. While there is no single dramatic event driving these shifts, the persistent decline has many wondering whether this signals deeper issues or simply reflects changing market sentiment around the pharmaceutical sector. Looking at a...

If you have been tracking Eaton (ETN) lately, you probably noticed some movement in its stock price that might give investors pause. Shares have dipped by about 7% over the past month, without any single significant news event capturing headlines. Sometimes, it is exactly these kinds of shifts that leave people wondering whether the market is adjusting to new information behind the scenes, perhaps related to anticipation around future growth or changing risk perceptions. Looking at the bigger...

If you have D.R. Horton in your portfolio or have been watching from the sidelines wondering if now is the time to buy, you are not alone. The stock has been anything but boring lately. Over the past month, shares are up roughly 24.5%. Looking back three months, that gain stretches to more than 37%. Even after accounting for a small dip over the last week, the recent surge shows investors are betting on growth, or at least a shift toward renewed optimism around homebuilders. D.R. Horton has...